IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors-Reference-Cited by-同舟云学术

IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors

Published:2020-11 Issue:11 Volume:28 Page:2379-2393
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Giuffrida Lauren,Sek Kevin,Henderson Melissa A.,House Imran G.,Lai Junyun,Chen Amanda X.Y.,Todd Kirsten L.,Petley Emma V.,Mardiana Sherly,Todorovski Izabela,Gruber Emily,Kelly Madison J.,Solomon Benjamin J.,Vervoort Stephin J.,Johnstone Ricky W.,Parish Ian A.,Neeson Paul J.,Kats Lev M.,Darcy Phillip K.,Beavis Paul A.^ORCID

Funder

National Health and Medical Research Council

National Breast Cancer Foundation

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference53 articles.

1. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains;Carpenito;Proc. Natl. Acad. Sci. USA,2009

2. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product;Finney;J. Immunol.,1998

3. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication;Zhong;Mol. Ther.,2010

4. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies;Tammana;Hum. Gene Ther.,2010

5. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression;Mardiana;Sci. Transl. Med.,2019

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

2. Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122+CXCR3+PD-1- memory T cells;Biomedicine & Pharmacotherapy;2024-10

3. Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies;Biomedicine & Pharmacotherapy;2024-09

4. CAR-T cell technologies that interact with the tumour microenvironment in solid tumours;Expert Review of Clinical Immunology;2024-07-17

5. Altered cancer metabolism and implications for next-generation CAR T-cell therapies;Pharmacology & Therapeutics;2024-07